BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25150257)

  • 1. A new prognostic score for AIDS-related lymphomas in the rituximab-era.
    Barta SK; Xue X; Wang D; Lee JY; Kaplan LD; Ribera JM; Oriol A; Spina M; Tirelli U; Boue F; Wilson WH; Wyen C; Dunleavy K; Noy A; Sparano JA
    Haematologica; 2014 Nov; 99(11):1731-7. PubMed ID: 25150257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.
    Barta SK; Samuel MS; Xue X; Wang D; Lee JY; Mounier N; Ribera JM; Spina M; Tirelli U; Weiss R; Galicier L; Boue F; Little RF; Dunleavy K; Wilson WH; Wyen C; Remick SC; Kaplan LD; Ratner L; Noy A; Sparano JA
    Ann Oncol; 2015 May; 26(5):958-966. PubMed ID: 25632071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
    Wyen C; Jensen B; Hentrich M; Siehl J; Sabranski M; Esser S; Gillor D; Müller M; Van Lunzen J; Wolf T; Bogner JR; Wasmuth JC; Christ H; Fätkenheuer G; Hoffmann C
    AIDS; 2012 Feb; 26(4):457-64. PubMed ID: 22112600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Prognostic Score Including the CD4/CD8 for AIDS-Related Lymphoma.
    Chen J; Liu X; Qin S; Ruan G; Lu A; Zhang J; Wu Y; Xie Z; Peng J
    Front Cell Infect Microbiol; 2022; 12():919446. PubMed ID: 35873145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
    Bower M; Gazzard B; Mandalia S; Newsom-Davis T; Thirlwell C; Dhillon T; Young AM; Powles T; Gaya A; Nelson M; Stebbing J
    Ann Intern Med; 2005 Aug; 143(4):265-73. PubMed ID: 16103470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Zhou Z; Sehn LH; Rademaker AW; Gordon LI; Lacasce AS; Crosby-Thompson A; Vanderplas A; Zelenetz AD; Abel GA; Rodriguez MA; Nademanee A; Kaminski MS; Czuczman MS; Millenson M; Niland J; Gascoyne RD; Connors JM; Friedberg JW; Winter JN
    Blood; 2014 Feb; 123(6):837-42. PubMed ID: 24264230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic variables and 4-year survival outcomes in CD20 Positive AIDS-Related Lymphoma in the Anti-retroviral treatment era: A Retrospective Review from a Single Centre in KwaZulu-Natal, South Africa.
    Rapiti N; Abdelatif N; Moosa MS
    PLoS One; 2022; 17(9):e0272282. PubMed ID: 36048870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
    Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I
    Platelets; 2019; 30(5):637-645. PubMed ID: 30047815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.
    Levine AM; Noy A; Lee JY; Tam W; Ramos JC; Henry DH; Parekh S; Reid EG; Mitsuyasu R; Cooley T; Dezube BJ; Ratner L; Cesarman E; Tulpule A
    J Clin Oncol; 2013 Jan; 31(1):58-64. PubMed ID: 23169503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
    Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
    Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
    Mounier N; Spina M; Gabarre J; Raphael M; Rizzardini G; Golfier JB; Vaccher E; Carbone A; Coiffier B; Chichino G; Bosly A; Tirelli U; Gisselbrecht C
    Blood; 2006 May; 107(10):3832-40. PubMed ID: 16410446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
    Kobayashi T; Tsutsumi Y; Sakamoto N; Nagoshi H; Yamamoto-Sugitani M; Shimura Y; Mizutani S; Matsumoto Y; Nishida K; Horiike S; Asano N; Nakamura S; Kuroda J; Taniwaki M
    Jpn J Clin Oncol; 2012 Nov; 42(11):1035-42. PubMed ID: 22984125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.
    Reid E; Nooka A; Blackmon J; Lechowicz MJ
    Curr Drug Deliv; 2012 Jan; 9(1):41-51. PubMed ID: 22023215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
    Kaplan LD; Lee JY; Ambinder RF; Sparano JA; Cesarman E; Chadburn A; Levine AM; Scadden DT
    Blood; 2005 Sep; 106(5):1538-43. PubMed ID: 15914552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
    Silverton A; Gunthel C; Adamski M; Mosunjac M; Nguyen ML
    AIDS Res Hum Retroviruses; 2014 Jul; 30(7):665-9. PubMed ID: 24707838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.
    Simonelli C; Tedeschi R; Gloghini A; Talamini R; Bortolin MT; Berretta M; Spina M; Morassut S; Vaccher E; De Paoli P; Carbone A; Tirelli U
    J Med Virol; 2009 May; 81(5):888-96. PubMed ID: 19319955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
    Miralles P; Berenguer J; Ribera JM; Rubio R; Mahillo B; Téllez MJ; Lacruz J; Valencia E; Santos J; Rodríguez-Arrondo F; Pintado V;
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):167-73. PubMed ID: 17117144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies.
    Castillo JJ; Echenique IA
    Am J Hematol; 2012 Mar; 87(3):330-3. PubMed ID: 22308010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.